We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers, PhRMA, BIO Push Back Against FDA Proposal for Nonclinical GLPs
The item has been added to your shopping cart.
Drugmakers, PhRMA, BIO Push Back Against FDA Proposal for Nonclinical GLPs
Several large drugmakers and industry groups commented on FDA’s proposal to require higher quality management standards for nonclinical studies used to support product applications.